US8158651B2ExpiredUtilityA1

Fentanyl composition for nasal administration

Assignee: GRARUP JESPERPriority: Jul 31, 2000Filed: Jan 24, 2007Granted: Apr 17, 2012
Est. expiryJul 31, 2020(expired)· nominal 20-yr term from priority
A61P 29/00A61P 25/00A61P 25/04A61K 47/10A61K 31/435A61P 23/00A61K 9/0043A61K 47/22A61K 31/4468A61K 31/445
48
PatentIndex Score
0
Cited by
186
References
12
Claims

Abstract

The treatment of acute pain with a sufficient dosage by intranasal administration of fentanyl results in a time to onset of action comparable to intravenous administration and a significantly faster onset of action than nasal titration of fentanyl. The nasal administration of a sufficient amount of fentanyl to obtain pain relief has lower maximum plasma concentrations comparable to intravenous administration and results in lower rates of adverse events like respiratory depression, nausea and vomiting. Compositions fur use in the method are also disclosed.

Claims

exact text as granted — not AI-modified
1. A device in combination with a liquid pharmaceutical composition comprising a fentanyl salt in a solvent comprising about 95-100% water at a concentration range equivalent to 0.5-20 mg/ml of fentanyl, said device comprising means for intranasal spray delivery of said composition in a dosage unit equivalent to 70 to 500 μg of fentanyl. 
     
     
       2. The device according to  claim 1 , wherein the concentration range is equivalent to 0.6-15 mg/ml fentanyl. 
     
     
       3. The device according to  claim 1 , wherein the concentration range is equivalent to 0.75-10 mg/ml fentanyl. 
     
     
       4. The device according to  claim 1 , wherein the concentration is equivalent to 1 mg/ml. 
     
     
       5. The device according to  claim 1 , wherein the concentration is equivalent to 2 mg/ml. 
     
     
       6. The device according to  claim 1 , wherein said fentanyl salt is fentanyl citrate. 
     
     
       7. The device according to  claim 2 , wherein said fentanyl salt is fentanyl citrate. 
     
     
       8. The device according to  claim 3 , wherein said fentanyl salt is fentanyl citrate. 
     
     
       9. The device according to  claim 4 , wherein said fentanyl salt is fentanyl citrate. 
     
     
       10. The device according to  claim 5 , wherein said fentanyl salt is fentanyl citrate. 
     
     
       11. The device according to  claim 1 , wherein the solvent is isotonic saline. 
     
     
       12. The device according to  claim 1 , wherein the solvent further comprises polyethylene glycol.

Join the waitlist — get patent alerts

Track US8158651B2 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.